Bottom line
Is MSJAX a good fund? The bottom line
MSJAX is the Class A share class of Global Endurance Portfolio, an actively managed global stock mutual fund from Morgan Stanley.
Its expense ratio is 1.35% — about $135 a year on every $10,000 invested, more expensive than 80% of global stock funds we track.
It returned +17.8% over one year, −4.7% a year over five years (as of Dec 31, 2025, per its prospectus).
With $16.2 million in net assets and 31 holdings, its largest position is Victoria PLC (19.0%) and the top 10 make up 61.6% of the portfolio.
This share class carries a front-end sales charge of up to 5.25%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.35%)
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 61.6% of assets
- Front-end sales load up to 5.25%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What MSJAX invests in
The Global Endurance Portfolio (the Fund) seeks long-term capital appreciation.
Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in equity securities of established and emerging companies located throughout the world, with capitalizations within the range of companies included in the MSCI All Country World Index. The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. In selecting securities for investment, the Adviser seeks to invest in companies with strong name recognition and sustainable competitive advantages. The Adviser typically favors companies with rising returns on invested capital, above-average business visibility, strong free cash flow generation and an attractive risk/reward. The Adviser typically focuses a significant portion of the Funds investments in a limited number of issuers, which may be in the same industry…
From the fund's prospectus (filed Apr 30, 2026).
MSJAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MSJAX | +17.8% | −4.7% | — |
| Global Stock median | +15.2% | +7.6% | +9.5% |
Source: Fund prospectus, as of Dec 31, 2025
What MSJAX costs
On a $10,000 investment, MSJAX's 1.35% expense ratio costs about $135 a year. The prospectus estimates $3,024 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.
MSJAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Victoria PLC | 19.05% |
| 2 | Roivant Sciences Ltd | 7.26% |
| 3 | Arbutus Biopharma Corp | 5.50% |
| 4 | Immunovant Inc | 4.86% |
| 5 | QXO Inc | 4.84% |
| 6 | Floor & Decor Holdings Inc | 4.83% |
| 7 | Teleflex Inc | 4.11% |
| 8 | Royalty Pharma PLC | 3.82% |
| 9 | DraftKings Inc | 3.70% |
| 10 | Calumet Inc | 3.63% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 61.6% of the fund. See all top 25 holdings and asset mix →